Patents by Inventor Ofra Levy-Hacham
Ofra Levy-Hacham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11877997Abstract: A regimen is described for providing early onset of action in the therapeutic treatment of rosacea including topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes about 1% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition is applied once daily for a period of at least about 2, 4, 8 or 12 weeks. Based on early onset of action, a primary measure of success is at least about 9%, primary measure of success being defined as a 2-grade improvement in IGA of clear or almost clear; and a secondary measure of success is at least about 40%, secondary measure of success being defined as mean inflammatory lesion count percent reduction from baseline, after at least about 2 weeks of treatment.Type: GrantFiled: January 25, 2021Date of Patent: January 23, 2024Assignee: Sol-Gel Technologies Ltd.Inventors: Ofer Toledano, Ofra Levy-Hacham, Ori Nov, Vered Ram
-
Patent number: 11865100Abstract: A regimen for the therapeutic treatment of rosacea in subjects aged 65 years and older, the regimen comprising topically applying to the skin of a subject aged 65 years and older in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 2 weeks, to achieve, in a group of such subjects, a success rate of at least about 15%, wherein the success rate is defined as the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition.Type: GrantFiled: January 21, 2021Date of Patent: January 9, 2024Assignee: Sol-Gel Technologies Ltd.Inventors: Ofer Toledano, Ofra Levy-Hacham, Ori Nov, Vered Ram
-
Publication number: 20230364050Abstract: A regimen is described for the therapeutic treatment of rosacea including topically applying to the skin of a subject in need of the treatment a pharmaceutical composition. The pharmaceutical composition includes about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient. The benzoyl peroxide is the only active ingredient in said pharmaceutical composition, and the pharmaceutical composition is applied once daily for a period of at least about 2 weeks, about 4 weeks, about 8 weeks or about 12 weeks. A decrease in Patient Assessment of Papulopustular Rosacea Signs and Symptoms (PAPSS) is at least about 40% after treatment with the pharmaceutical composition for about 4 weeks, and a decrease in Patient Assessment of Papulopustular Rosacea Impacts (PAPI) is from about 60% to about 70% after treatment with the pharmaceutical composition for at least about 8 weeks.Type: ApplicationFiled: July 24, 2023Publication date: November 16, 2023Inventors: Ofer TOLEDANO, Ofra LEVY-HACHAM, Ori NOV, Vered RAM
-
Publication number: 20230076766Abstract: A regimen for the therapeutic treatment of rosacea in a subject aged 35-64 years, the regimen comprising topically applying a pharmaceutical composition to the skin of the subject in need of said treatment, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 2 weeks, at least about 4 weeks, at least about 8 weeks, or at least about 12 weeks, to achieve, in a group of such subjects, a success rate of at least about 12%, at least about 27%, at least about 38%, or at least about 42%, respectively, and wherein the success rate is defined as the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition.Type: ApplicationFiled: August 22, 2022Publication date: March 9, 2023Inventors: Ofer TOLEDANO, Ofra LEVY-HACHAM, Ori NOV, Vered RAM
-
Publication number: 20220362204Abstract: A regimen for the long-term therapeutic treatment of rosacea. The regimen includes topically applying to the skin of a subject in need of said treatment a pharmaceutical composition. The pharmaceutical composition includes about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient. The benzoyl peroxide is the only active ingredient in said pharmaceutical composition, and the pharmaceutical composition is applied once daily for a period of up to about 40 weeks to about 52 weeks, to achieve, in a group of such subjects, a success rate of about 75% to about 85%.Type: ApplicationFiled: July 20, 2022Publication date: November 17, 2022Inventors: Ofer TOLEDANO, Ofra LEVY-HACHAM, Ori NOV, Vered RAM
-
Patent number: 11426378Abstract: A regimen for the long-term therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject. The pharmaceutical composition includes about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient. The benzoyl peroxide is the only active ingredient in the pharmaceutical composition, and the pharmaceutical composition is applied once daily for a period of about 52 weeks, to achieve, in a group of such subjects, a success rate of about 75%.Type: GrantFiled: February 19, 2020Date of Patent: August 30, 2022Assignee: SOL-GEL TECHNOLOGIES LTD.Inventors: Ofer Toledano, Ofra Levy-Hacham, Ori Nov, Vered Ram
-
Publication number: 20220062285Abstract: The present invention, in some embodiments, relates to a method of treatment, prevention or alleviation of Palmoplantar Keratoderma (PPK) or Olmsted syndrome in a patient in need thereof, comprising a debridement step followed by topical administration of a composition comprising at least one Epidermal Growth Factor Receptor (EGFR) inhibitor.Type: ApplicationFiled: November 9, 2021Publication date: March 3, 2022Applicant: Sol-Gel Technologies Ltd.Inventors: Moshe ARKIN, Marcel ZIGHELBOIM, Ofra LEVY-HACHAM, Ori NOV
-
Publication number: 20210169841Abstract: A regimen for the therapeutic treatment of rosacea in subjects aged 65 years and older, the regimen comprising topically applying to the skin of a subject aged 65 years and older in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 2 weeks, to achieve, in a group of such subjects, a success rate of at least about 15%, wherein the success rate is defined as the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition.Type: ApplicationFiled: January 21, 2021Publication date: June 10, 2021Inventors: Ofer TOLEDANO, Ofra LEVY-HACHAM, Ori NOV, Vered RAM
-
Publication number: 20210145790Abstract: A regimen is described for providing early onset of action in the therapeutic treatment of rosacea including topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes about 1% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition is applied once daily for a period of at least about 2, 4, 8 or 12 weeks. Based on early onset of action, a primary measure of success is at least about 9%, primary measure of success being defined as a 2-grade improvement in IGA of clear or almost clear; and a secondary measure of success is at least about 40%, secondary measure of success being defined as mean inflammatory lesion count percent reduction from baseline, after at least about 2 weeks of treatment.Type: ApplicationFiled: January 25, 2021Publication date: May 20, 2021Inventors: Ofer TOLEDANO, Ofra LEVY-HACHAM, Ori NOV, Vered RAM
-
Publication number: 20210113511Abstract: The present application is directed to regimens, methods of treatment, and compositions for the treatment of acne in a subject suffering therefrom.Type: ApplicationFiled: December 30, 2020Publication date: April 22, 2021Applicant: Sol-Gel Technologies Ltd.Inventors: Ofer Toledano, Ofra Levy-Hacham, Rinat Mizrahi
-
Patent number: 10945987Abstract: A regimen is described for providing early onset of action in the therapeutic treatment of rosacea including topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes about 1% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition is applied once daily for a period of at least about 2, 4, 8 or 12 weeks. Based on early onset of action, a primary measure of success is at least about 9%, primary measure of success being defined as a 2-grade improvement in IGA of clear or almost clear; and a secondary measure of success is at least about 40%, secondary measure of success being defined as mean inflammatory lesion count percent reduction from baseline, after at least about 2 weeks of treatment.Type: GrantFiled: February 19, 2020Date of Patent: March 16, 2021Assignee: SOL-GEL TECHNOLOGIES LTD.Inventors: Ofer Toledano, Ofra Levy-Hacham, Ori Nov, Vered Ram
-
Patent number: 10933046Abstract: A regimen for the therapeutic treatment of rosacea in subjects aged 65 years and older, the regimen comprising topically applying to the skin of a subject aged 65 years and older in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 2 weeks, to achieve, in a group of such subjects, a success rate of at least about 15%, wherein the success rate is defined as the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition.Type: GrantFiled: February 19, 2020Date of Patent: March 2, 2021Assignee: SOL-GEL TECHNOLOGIES, LTD.Inventors: Ofer Toledano, Ofra Levy-Hacham, Ori Nov, Vered Ram
-
Publication number: 20200261400Abstract: A regimen for the long-term therapeutic treatment of rosacea. The regimen includes topically applying to the skin of a subject in need of said treatment a pharmaceutical composition. The pharmaceutical composition includes about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient. The benzoyl peroxide is the only active ingredient in said pharmaceutical composition, and the pharmaceutical composition is applied once daily for a period of up to about 40 weeks to about 52 weeks, to achieve, in a group of such subjects, a success rate of about 75% to about 85%.Type: ApplicationFiled: February 19, 2020Publication date: August 20, 2020Inventors: Ofer TOLEDANO, Ofra LEVY-HACHAM, Ori NOV, Vered RAM
-
Publication number: 20200261402Abstract: A regimen for the therapeutic treatment of moderate to severe erythema symptoms in rosacea patients, the regimen comprising topically applying to the skin of a subject in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 12 weeks, to achieve a percentage decrease of about 60% in a population exhibiting moderate to severe erythema symptoms when measured at about 12 weeks after initial treatment of the population with the pharmaceutical composition.Type: ApplicationFiled: February 19, 2020Publication date: August 20, 2020Inventors: Ofer TOLEDANO, Ofra LEVY-HACHAM, Ori NOV, Vered RAM
-
Publication number: 20200261397Abstract: A regimen is described for providing early onset of action in the therapeutic treatment of rosacea including topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes about 1% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition is applied once daily for a period of at least about 2, 4, 8 or 12 weeks. Based on early onset of action, a primary measure of success is at least about 9%, primary measure of success being defined as a 2-grade improvement in IGA of clear or almost clear; and a secondary measure of success is at least about 40%, secondary measure of success being defined as mean inflammatory lesion count percent reduction from baseline, after at least about 2 weeks of treatment.Type: ApplicationFiled: February 19, 2020Publication date: August 20, 2020Inventors: Ofer TOLEDANO, Ofra LEVY-HACHAM, Ori NOV, Vered RAM
-
Publication number: 20200261395Abstract: A regimen for the therapeutic treatment of rosacea, which includes topically applying to the skin of a subject a pharmaceutical composition. The pharmaceutical composition includes about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in the pharmaceutical composition. The pharmaceutical composition is applied once daily for a period of about 2 weeks, about 4 weeks, about 8 weeks and about 12 weeks. The treatment regimen achieves a success rate of at least about 6%, wherein the success rate is defined as a percentage increase in the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition. The treatment regimen may also achieve significantly greater reduction in inflammatory lesion counts compared to treatment with vehicle alone.Type: ApplicationFiled: February 19, 2020Publication date: August 20, 2020Inventors: Ofer TOLEDANO, Ofra LEVY-HACHAM, Ori NOV, Vered RAM
-
Publication number: 20200261399Abstract: A regimen for the therapeutic treatment of rosacea in subjects aged 65 years and older, the regimen comprising topically applying to the skin of a subject aged 65 years and older in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 2 weeks, to achieve, in a group of such subjects, a success rate of at least about 15%, wherein the success rate is defined as the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition.Type: ApplicationFiled: February 19, 2020Publication date: August 20, 2020Inventors: Ofer TOLEDANO, Ofra LEVY-HACHAM, Ori NOV, Vered RAM
-
Publication number: 20200261401Abstract: A regimen is described for the therapeutic treatment of rosacea including topically applying to the skin of a subject in need of the treatment a pharmaceutical composition. The pharmaceutical composition includes about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient. The benzoyl peroxide is the only active ingredient in said pharmaceutical composition, and the pharmaceutical composition is applied once daily for a period of at least about 2 weeks, about 4 weeks, about 8 weeks or about 12 weeks. A decrease in Patient Assessment of Papulopustular Rosacea Signs and Symptoms (PAPSS) is at least about 40% after treatment with the pharmaceutical composition for about 4 weeks, and a decrease in Patient Assessment of Papulopustular Rosacea Impacts (PAPI) is from about 60% to about 70% after treatment with the pharmaceutical composition for at least about 8 weeks.Type: ApplicationFiled: February 19, 2020Publication date: August 20, 2020Inventors: Ofer TOLEDANO, Ofra LEVY-HACHAM, Ori NOV, Vered RAM
-
Publication number: 20150094260Abstract: The present disclosure provides a buffered ophthalmic composition for formulation of topically administrable suspensions useful for treating eye disorders by promoting wound healing, delivery of pharmaceutically active agents, and lubricating the eye. In particular the ophthalmic composition includes a buffer solution compatible with application to a mammalian eye, wherein the buffer provides increased mechanism of action of pharmaceutically active agents as well as therapeutic qualities. The ophthalmic composition exhibits dual therapeutic action to alleviate various eye disorders as it concomitantly treats corneal ulcerations and excessive inflammation which results from various eye injuries.Type: ApplicationFiled: August 14, 2014Publication date: April 2, 2015Inventors: Liora BRAIMAN-WIKSMAN, Yuval Sagiv, Ofra Levy-Hacham, Tamar Tennenbaum
-
Publication number: 20140227243Abstract: The present disclosure relates to compositions and methods for accelerating the healing process of wounds, increasing the closure of skin wounds, and decreasing inflammation at the site of a skin wound. Specifically, the disclosure relates to compositions comprising a delta-PKC activator, an alpha-PKC inhibitor, and a pharmaceutically acceptable carrier that is free of Ca2+ and Mg2+ cations. The disclosure also relates to compositions comprising an insulin or insulin analog and a pharmaceutically acceptable carrier that is free of Ca2+ and Mg2+ cations.Type: ApplicationFiled: February 15, 2013Publication date: August 14, 2014Inventors: Liora BRAIMAN-WIKSMAN, Tamar TENNENBAUM, Inessa SOLOMONIK, Ofra LEVY-HACHAM, Ephraim BRENER